A real-world comparison of the effectiveness and safety of vedolizumab and anti-TNF therapies in early treatment initiation with first-line biologic therapy in ulcerative colitis: Results from EVOLVE

被引：0
|
作者：
Mantzaris, G. [1 ]
Bressler, B. [2 ]
Kopylov, U. [3 ]
Bassel, M. [4 ]
Brett, N. [4 ]
Colby, C. [5 ]
Lopez, C. [6 ]
Saha, S. [7 ]
Kifnidi, C. [8 ]
Agboton, C. [9 ]
Adsul, S. [9 ]
Demuth, D. [10 ]
Luo, M. [11 ]
Wang, S. [11 ]
Yarur, A. [12 ]
机构：
[1] Evangelismos Med Ctr, Dept Gastroenterol, Athens, Greece
[2] St Pauls Hosp, Dept Gastroenterol, Vancouver, BC, Canada
[3] Sheba Med Ctr, Dept Gastroenterol, Tel Aviv, Israel
[4] Evidera, Real World Evidence, Montreal, PQ, Canada
[5] Evidera, Real World Evidence, San Francisco, CA USA
[6] Takeda Pharmaceut USA Inc, Dept Med Affairs, Deerfield, IL USA
[7] Takeda Canada Inc, Dept Med Affairs, Oakville, ON, Canada
[8] Takeda Hellas SA Athens, Dept Med Affairs, Athens, Greece
[9] Takeda Pharmaceut Int AG, Dept Global Med Affairs, Zurich, Switzerland
[10] Takeda Pharmaceut Int, Evidence Generat & Publicat, Singapore, Singapore
[11] Takeda Pharmaceut Int, Global Outcomes Res, Boston, MA USA
[12] Med Coll Wisconsin, Dept Gastroenterol, Milwaukee, WI 53226 USA
来源：
JOURNAL OF CROHNS & COLITIS | 2020年 / 14卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
DOP55
引用
收藏
页码：S092 / S094
页数：3
相关论文
共 50 条
  • [41] Real-world effectiveness and safety of vedolizumab induction therapy for ulcerative colitis: A prospective nationwide Polish observational study
    Zagorowicz, Edyta
    Cichoz-Lach, Halina
    Kopertowska-Majchrzak, Maria
    Eder, Piotr
    Stawczyk-Eder, Kamila
    Talar-Wojnarowska, Renata
    Zatorski, Hubert
    Solarska-Polchlopek, Anna
    Filip, Rafal
    Janiak, Maria
    Skrobot, Krzysztof
    Klopocka, Maria
    Liebert, Ariel
    Kaczka, Aleksandra
    Wojciechowski, Krzysztof
    Drygala, Szymon
    Michalak, Agata
    ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, 2024, 33 (01): : 69 - 77
  • [42] TREATMENT PERSISTENCE RATES WITH TOFACITINIB IN A REAL-WORLD COHORT OF ANTI-TNF REFRACTORY ULCERATIVE COLITIS PATIENTS
    Conley, Thomas
    Colclough, James
    Liu, Eleanor
    Razanskaite, Violeta
    Jakobek, William
    Limdi, Jimmy
    Flanagan, Paul
    Subramanian, Sreedhar
    GUT, 2021, 70 : A88 - A89
  • [43] Editorial: real-world evidence of tofacitinib and vedolizumab in ulcerative colitis-are we one step closer to better positioning therapies after anti-TNF failure?
    Ernest-Suarez, Kenneth
    Lu, Cathy
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2023, 57 (06) : 733 - 734
  • [44] Real-world clinical effectiveness and safety of vedolizumab and ustekinumab in biologic-naive patients with Crohn's disease: Results from the EVOLVE Expansion study
    Ferrante, M.
    Christensen, B.
    Bressler, B.
    Brett, N.
    Bassel, M.
    Kamble, P.
    Adsul, S.
    Gianchetti, L.
    Scharl, M.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 768 - 769
  • [45] Real-world clinical effectiveness and safety of vedolizumab and ustekinumab in biologic-naive patients with Crohn's disease: Results from the EVOLVE Expansion study
    Ferrante, M.
    Christensen, B.
    Bressler, B.
    Brett, N.
    Bassel, M.
    Kamble, P.
    Adsul, S.
    Gianchetti, L.
    Scharl, M.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2023, 38 : 116 - 117
  • [46] REAL-WORLD CLINICAL EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB AND USTEKINUMAB IN BIOLOGIC-NAIVE PATIENTS WITH CROHN'S DISEASE: RESULTS FROM THE EVOLVE EXPANSION STUDY
    Ferrante, Marc
    Christensen, Britt
    Bressler, Brian
    Brett, Neil R.
    Bassel, Marielle
    Kamble, Pravin
    Adsul, Shashi
    Gianchetti, Lauren
    Scharl, Michael M.
    GASTROENTEROLOGY, 2023, 164 (06) : S5 - S5
  • [47] Real-world drug treatment costs for ulcerative colitis and Crohn's disease patients treated with vedolizumab vs. anti-TNFα: Results from a German retrospective chart review study
    Campbell-Hill, S.
    Stein, D.
    Soni, M.
    Coombs, C.
    Ratsch, B.
    Khalid, J. M.
    Minda, K.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S504 - S504
  • [48] Cost-Effectiveness of Vedolizumab as a First-Line Advanced Therapy Versus Adalimumab Treatment Sequences for Ulcerative Colitis in Italy
    Salcedo, Jonathan
    Hill-McManus, Daniel
    Hardern, Chloe
    Opeifa, Oyin
    Viti, Raffaella
    Siviero, Ludovica
    Roscini, Antonio Saverio
    Di Martino, Gennaro
    PHARMACOECONOMICS-OPEN, 2024, 8 (05) : 701 - 714
  • [49] Closing the Gap: the Real-World Risk of Serious Infections With Vedolizumab in Comparison With Anti-TNF Therapy in Inflammatory Bowel Disease
    Ahmed, Waseem
    Scott, Frank, I
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2022, 20 (02) : E28 - E30
  • [50] Editorial: real-world evidence of tofacitinib and vedolizumab in ulcerative colitis-are we one step closer to better positioning therapies after anti-TNF failure? Authors' reply
    Buisson, Anthony
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2023, 57 (06) : 735 - 736
12345